122 results
Keyword Sitagliptin Remove keyword
-
List item
Sitagliptin product-specific bioequivalence guidance
Last updated: 01/11/2016Sitagliptin product-specific bioequivalence … Bioequivalence, generics, sitagliptin …
-
List item
National expert: Neli Jakuboniene, Lithuania States Medicines Control Agency (updated)
- Declaration of interests - 80.37 KB | PDF
- Curriculum Vitae - 19.67 KB | PDF
TECOS Study Group. Safety of sitagliptin in patients with type 2 diabetes … TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes … Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators … -
List item
National expert: Angela Garau, Italian Medicines Agency (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 22.61 KB | PDF
-
List item
National expert: Ursula Wippo, Federal Institute for Drugs and Medical Devices (updated)
- Declaration of interests - 79.8 KB | PDF
- Curriculum Vitae - 17.8 KB | PDF
Mobocertinib) - Janumet (sitagliptin+ metformin) - Mektovi and … -
List item
National expert: Daniele Focosi, European Medicines Agency (updated)
- Declaration of interests - 80.48 KB | PDF
- Curriculum Vitae - 62.46 KB | PDF
-
List item
National expert: Robert Porszasz, National Institute of Pharmacy and Nutrition (updated)
- Declaration of interests - 80.17 KB | PDF
- Curriculum Vitae - 29.97 KB | PDF
anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice. Regul … -
List item
National expert: Jochen Seufert, European Medicines Agency (updated)
- Declaration of interests - 82.48 KB | PDF
- Curriculum Vitae - 48.99 KB | PDF
-
List item
Product-specific bioequivalence guidance
Last updated: 06/10/2015 -
List item
PRAC recommendations on safety signals (updated)
Last updated: 04/07/2022 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 04/07/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2022 (updated)
European Medicines Agency, Amsterdam, the Netherlands, from 20/06/2022 to 23/06/2022, Last updated: 20/06/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 31/05/2022 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 17/06/2022 -
List item
Medicines for human use under evaluation
Last updated: 11/03/2022medicines N N N 10/28/21 Sirolimus Chemicals Immunosuppressants N Y Y 12/24/21 Sitagliptin/metformin Chemicals Medicines used …
-
List item
EMA 2022 event supporting materials (updated)
Last updated: 14/06/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 May 2022
European Medicines Agency, Amsterdam, the Netherlands, from 16/05/2022 to 19/05/2022, Last updated: 16/05/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 July 2021
European Medicines Agency, Amsterdam, the Netherlands, from 05/07/2021 to 08/07/2021, Last updated: 10/05/2022 -
List item
PDCO: meeting archive 2015-2017
Last updated: 19/04/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 11-14 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 11/10/2021 to 14/10/2021, Last updated: 20/01/202210 3.1.4. sitagliptin fumarate - EMEA/H/C/005741 … -
List item
Committee for Medicinal Products for Human Use (CHMP): 24-27 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 24/01/2022 to 27/01/2022, Last updated: 16/03/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 17/05/2021 to 20/05/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 March 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/03/2021 to 25/03/2021, Last updated: 07/12/2021 -
List item
Newsletters
Last updated: 15/02/2022 -
List item
Annual reports and work programmes (updated)
Last updated: 10/06/2022 -
List item
Download medicine data
Last updated: 02/12/2021